论文部分内容阅读
据美国波士顿Dana-Farber癌症研究所的科学家们报道,一种新的疫苗可提高进展型非小细胞肺癌(NSCLC)患者的天然免疫反应,表明该疫苗具有潜在治疗肺癌的效果,无毒性,可较好耐受。研究结果发表在近期出版的《临床肿瘤学杂志》上,旨在评估其安全性的Ⅰ期临床试验将进一步推动抗NSCLC疫苗的研制开发。非小细胞肺癌在所有难治
According to scientists at the Dana-Farber Cancer Institute in Boston, a new vaccine is reported to improve the innate immune response in patients with advanced non-small cell lung cancer (NSCLC), indicating that the vaccine has the potential of being effective in treating lung cancer without toxicity Better tolerated. The findings, published in the recently published issue of the Journal of Clinical Oncology, aim to assess the safety of Phase I clinical trials that will further advance the development of anti-NSCLC vaccines. Non-small cell lung cancer is refractory in all